207 related articles for article (PubMed ID: 30352573)
1. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone.
Chen H; He R; Shi X; Zhou M; Zhao C; Zhang H; Qin R
BMC Cancer; 2018 Oct; 18(1):1034. PubMed ID: 30352573
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Li D; Chen C; Zhou Y; Chen R; Fan X; Bi Z; Li Z; Liu Y
Medicine (Baltimore); 2015 Sep; 94(35):e1345. PubMed ID: 26334891
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
Jin SF; Fan ZK; Pan L; Jin LM
Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):236-244. PubMed ID: 28603091
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
[TBL] [Abstract][Full Text] [Related]
7. The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile.
Liu Y; Huang QK; Hong WD; Wu JM; Sun XC
Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):254-60. PubMed ID: 25304193
[TBL] [Abstract][Full Text] [Related]
8. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy and radiotherapy for advanced pancreatic cancer.
Chin V; Nagrial A; Sjoquist K; O'Connor CA; Chantrill L; Biankin AV; Scholten RJ; Yip D
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD011044. PubMed ID: 29557103
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone.
Xie DR; Liang HL; Wang Y; Guo SS; Yang Q
World J Gastroenterol; 2006 Nov; 12(43):6973-81. PubMed ID: 17109519
[TBL] [Abstract][Full Text] [Related]
11. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials.
Ciliberto D; Botta C; Correale P; Rossi M; Caraglia M; Tassone P; Tagliaferri P
Eur J Cancer; 2013 Feb; 49(3):593-603. PubMed ID: 22989511
[TBL] [Abstract][Full Text] [Related]
12. An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?
Tu C; Zheng F; Wang JY; Li YY; Qian KQ
Asian Pac J Cancer Prev; 2015; 16(14):5681-6. PubMed ID: 26320435
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.
Zhang XW; Ma YX; Sun Y; Cao YB; Li Q; Xu CA
Target Oncol; 2017 Jun; 12(3):309-321. PubMed ID: 28353074
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer: A Meta-analysis.
Yu Z; Zhong W; Tan ZM; Wang LY; Yuan YH
Am J Clin Oncol; 2015 Jun; 38(3):322-5. PubMed ID: 23934134
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of gemcitabine-based chemotherapy in metastatic breast cancer: a meta-analysis of randomized controlled trials.
Li W; Wang H; Li X
Curr Med Res Opin; 2013 Nov; 29(11):1443-52. PubMed ID: 23927481
[TBL] [Abstract][Full Text] [Related]
16. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
Oettle H; Neuhaus P; Hochhaus A; Hartmann JT; Gellert K; Ridwelski K; Niedergethmann M; Zülke C; Fahlke J; Arning MB; Sinn M; Hinke A; Riess H
JAMA; 2013 Oct; 310(14):1473-81. PubMed ID: 24104372
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.
Heinemann V; Boeck S; Hinke A; Labianca R; Louvet C
BMC Cancer; 2008 Mar; 8():82. PubMed ID: 18373843
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials.
Ouyang G; Wu Y; Liu Z; Lu W; Li S; Hao S; Pan G
Medicine (Baltimore); 2021 Dec; 100(48):e27870. PubMed ID: 35049189
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer.
Yoshitomi H; Togawa A; Kimura F; Ito H; Shimizu H; Yoshidome H; Otsuka M; Kato A; Nozawa S; Furukawa K; Miyazaki M;
Cancer; 2008 Nov; 113(9):2448-56. PubMed ID: 18823024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
